Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- KYTX
- Price
- 10.51
- Stock movement up
- +1.03 (10.86%)
- Company name
- Kyverna Therapeutics, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 626.47M
- Ent value
- 627.51M
- Price/Sales
- 309.52
- Price/Book
- 4.12
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 214.67%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KYTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 309.52 |
| Price to Book | 4.12 |
| EV to Sales | 310.04 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 59.61M |
| EPS (TTM) | -3.71 |
| FCF per share (TTM) | -3.65 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.02M |
| Gross profit (TTM) | -1.99M |
| Operating income (TTM) | -171.59M |
| Net income (TTM) | -160.99M |
| EPS (TTM) | -3.71 |
| EPS (1y forward) | -3.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -98.52% |
| Operating margin (TTM) | -8477.57% |
| Profit margin (TTM) | -7954.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.16M |
| Net receivables | 0.00 |
| Total current assets | 174.93M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 9.90M |
| Total assets | 187.16M |
| Accounts payable | 3.02M |
| Short/Current long term debt | 5.02M |
| Total current liabilities | 33.87M |
| Total liabilities | 35.21M |
| Shareholder's equity | 151.95M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -157.25M |
| Capital expenditures (TTM) | 1.13M |
| Free cash flow (TTM) | -158.37M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -105.95% |
| Return on Assets | -86.02% |
| Return on Invested Capital | -103.44% |
| Cash Return on Invested Capital | -101.76% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.56 |
| Daily high | 10.55 |
| Daily low | 9.53 |
| Daily Volume | 1.27M |
| All-time high | 30.10 |
| 1y analyst estimate | 29.60 |
| Beta | - |
| EPS (TTM) | -3.71 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KYTX | S&P500 | |
| Current price drop from All-time high | -65.08% | -0.89% |
| Highest price drop | -93.92% | -19.00% |
| Date of highest drop | 16 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -84.91% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
626.47M
Marketcap category
Small-cap
Description
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Employees
129
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page